Equities Analysts Offer Predictions for Evolus Q3 Earnings

Key Points

• Equities analysts at Leerink Partners have lowered their Q3 2025 EPS estimates for Evolus to ($0.26), down from a previous forecast of ($0.25), while the full-year consensus estimate stands at ($0.61) EPS.
• The current consensus rating for Evolus is Hold, with three analysts rating it as a Buy, one as a Hold, and one as a Sell, alongside a consensus price target of $21.25.
• Insider trading activity has seen CMO Tomoko Yamagishi-Dressler sell shares, while Director Brady Stewart significantly increased his holdings, buying 30,000 shares at $6.82 each, indicating differing levels of confidence among executives.

Evolus, Inc. (NASDAQ:EOLS - Free Report) - Equities research analysts at Leerink Partnrs decreased their Q3 2025 earnings per share (EPS) estimates for shares of Evolus in a note issued to investors on Monday, October 6th. Leerink Partnrs analyst M. Goodman now anticipates that the company will post earnings per share of ($0.26) for the quarter, down from their previous forecast of ($0.25). The consensus estimate for Evolus' current full-year earnings is ($0.61) per share. Leerink Partnrs also issued estimates for Evolus' FY2026 earnings at ($0.06) EPS.

Other analysts also recently issued reports about the company. BTIG Research reiterated a "buy" rating and set a $18.00 price target on shares of Evolus in a report on Monday, September 8th. Needham & Company LLC reiterated a "hold" rating and set a $22.00 price target on shares of Evolus in a report on Wednesday, August 6th. Wall Street Zen downgraded Evolus from a "hold" rating to a "sell" rating in a report on Saturday, August 9th. HC Wainwright decreased their price target on Evolus from $27.00 to $20.00 and set a "buy" rating for the company in a report on Wednesday, August 6th. Finally, Weiss Ratings reiterated a "sell (e+)" rating on shares of Evolus in a report on Saturday, September 27th. Three research analysts have rated the stock with a Buy rating, one has assigned a Hold rating and one has issued a Sell rating to the company's stock. Based on data from MarketBeat, the company currently has a consensus rating of "Hold" and a consensus price target of $21.25.

Evolus Trading Down 0.8%

Shares of Evolus stock opened at $6.21 on Thursday. The business has a 50-day moving average price of $6.96 and a two-hundred day moving average price of $9.05. Evolus has a 1-year low of $5.71 and a 1-year high of $17.82. The company has a market cap of $401.66 million, a P/E ratio of -6.34 and a beta of 1.04.

Insider Activity

In other Evolus news, CMO Tomoko Yamagishi-Dressler sold 5,722 shares of the business's stock in a transaction that occurred on Friday, August 22nd. The stock was sold at an average price of $7.51, for a total transaction of $42,972.22. Following the completion of the sale, the chief marketing officer directly owned 89,949 shares of the company's stock, valued at approximately $675,516.99. The trade was a 5.98% decrease in their position. The sale was disclosed in a document filed with the SEC, which is accessible through this hyperlink. Also, Director Brady Stewart bought 30,000 shares of the company's stock in a transaction dated Friday, August 15th. The stock was bought at an average price of $6.82 per share, for a total transaction of $204,600.00. Following the acquisition, the director directly owned 88,629 shares of the company's stock, valued at approximately $604,449.78. This represents a 51.17% increase in their ownership of the stock. The disclosure for this purchase can be found here. Company insiders own 5.90% of the company's stock.

Institutional Inflows and Outflows

A number of large investors have recently modified their holdings of the stock. Vanguard Group Inc. lifted its holdings in shares of Evolus by 2.0% in the first quarter. Vanguard Group Inc. now owns 3,234,068 shares of the company's stock valued at $38,906,000 after purchasing an additional 62,664 shares in the last quarter. Frazier Life Sciences Management L.P. bought a new position in shares of Evolus in the second quarter valued at approximately $22,431,000. Soleus Capital Management L.P. lifted its holdings in shares of Evolus by 96.4% in the second quarter. Soleus Capital Management L.P. now owns 2,119,000 shares of the company's stock valued at $19,516,000 after purchasing an additional 1,039,842 shares in the last quarter. Frontier Capital Management Co. LLC lifted its holdings in shares of Evolus by 37.9% in the second quarter. Frontier Capital Management Co. LLC now owns 1,664,828 shares of the company's stock valued at $15,333,000 after purchasing an additional 457,533 shares in the last quarter. Finally, Millennium Management LLC lifted its position in shares of Evolus by 1.7% during the 1st quarter. Millennium Management LLC now owns 1,392,028 shares of the company's stock worth $16,746,000 after buying an additional 23,605 shares in the last quarter. Institutional investors own 90.69% of the company's stock.

About Evolus

Evolus, Inc, a performance beauty company, focuses on delivering products in the cash-pay aesthetic market in the United States, Canada, and Europe. The company offers Jeuveau, a proprietary 900 kilodalton purified botulinum toxin type A formulation for the temporary improvement in the appearance of moderate to severe glabellar lines in adults.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.